Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
View Patent ↗Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid for treating urinary incontinence is disclosed.
1. A method of treating urinary incontinence in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid is crystalline.
3. The method of claim 1 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid or pharmaceutically acceptable salt thereof is (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid.
4. The method of claim 1 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid is administered orally.
5. The method of claim 4 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid is formulated in a sustained release oral dosage form.
6. The method of claim 1 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid is administered in an amount from about 5 mg-equivalents (R)-baclofen/day to about 100 mg-equivalents (R)-baclofen/day.
7. The method of claim 1 , wherein the urinary incontinence is functional incontinence.
8. The method of claim 1 , wherein the urinary incontinence is urge incontinence.
9. The method of claim 1 , wherein the urinary incontinence is stress incontinence.
10. The method of claim 1 , wherein the urinary incontinence is overactive bladder.
11. The method of claim 10 , wherein the overactive bladder is characterized by frequency and nocturia.
12. The method of claim 1 , wherein the urinary incontinence is mixed incontinence.
13. The method of claim 1 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid is formulated as a pharmaceutical composition comprising the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid and a pharmaceutically acceptable vehicle.
14. The method of claim 13 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid is crystalline.
15. The method of claim 13 , wherein the pharmaceutical composition is a sustained release oral formulation.
16. The method of claim 13 , wherein the pharmaceutical composition is administered in an amount from about 5 mg-equivalents R-baclofen/day to about 100 mg-equivalents R-baclofen/day.
17. The method of claim 1 , comprising administering a muscarinic receptor antagonist.
18. The method of claim 17 , wherein the muscarinic receptor antagonist is selected from oxybutynin, tolterodine, trospium, solifenacin, and darifenacin.
19. A method of treating urinary incontinence in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle.
20. The method of claim 19 , wherein the (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid is crystalline.